A man of commitment

A man of commitment

6 February 2015

Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial. This outstanding commitment was acknowledged by Melanoma Institute Australia’s Executive Director, Professor John Thompson, who has been involved in the trial and Joel’s care from the beginning.

At age 33, Joel was diagnosed with stage 3 melanoma originating from a small mole on his thigh. He was referred to Professor Thompson in December 2004 and was invited to participate in the clinical trial. The MSLT-II trial is assessing whether complete lymph node dissection or monitoring with ultrasound is the most effective way at treating patients who have a positive sentinel lymph node biopsy. Interim findings from the study are expected in the next year or so, with the final results  being published after the decade-long follow-up of the last patient is undertaken. This international trial has only recently completed recruiting and has 1937 patients from around the world involved in the trial.

Joel was randomised on the trial to receive follow-up with ultrasound. His commitment throughout the past decade has been regular appointments and ultrasounds ranging from every 4 months in the beginning to every year after 5 years. A Sydney local for most of the decade, Joel spent 2 years during the trial flying to Sydney from Perth every 6 months to stay on the trial.

“I am a stubborn man! I will see things through to the end!” says Joel when asked about why he stayed on the trial for the whole decade.

With a family history of cancer, Joel realised that his participation would have long-lasting benefits beyond his own melanoma journey. “I knew I was getting the best possible care on the trial, but I also realised that my participation would have benefits to melanoma patients around the world.”

A decade on, Joel is healthy and his melanoma hasn’t progressed. Although getting melanoma was a “surreal blur” in the beginning, his journey has now given him a fresh perspective on life.

“Having melanoma has helped me re-evaluate what is important in life and given me clearer perspective,” says Joel. “Two years ago I was made redundant, and instead of thinking that the end of the world had come, I thought ‘well, things could be worse!’”. 

International Clinical Trials Day 2019
20 May 2019

International Clinical Trials Day 2019

Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.

Emma Betts' legacy will live on
17 May 2019

Emma Betts' legacy will live on

“I’m the age Emma was when she passed away. It almost feels unfair, that she has to not be here for me to be able to do this. But I will use this opportunity to push as hard as I can to reach our collective goal of zero deaths from melanoma.”

Support PBS listing for adjuvant treatments of resected Stage III melanoma
13 May 2019

Support PBS listing for adjuvant treatments of resected Stage III melanoma

As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.

Support PBS listing for pembrolizumab
06 May 2019

Support PBS listing for pembrolizumab

As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.

How are the Premier's Awards helping cancer researchers?
02 May 2019

How are the Premier's Awards helping cancer researchers?

MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.

Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
19 Mar 2019

Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects

Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.

Making a difference to many
15 Mar 2019

Making a difference to many

Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.

Aussie icon Sophie Monk calls on Australians to get behind Melanoma March
26 Feb 2019

Aussie icon Sophie Monk calls on Australians to get behind Melanoma March

Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.

Melanoma breakthrough paves way for personalised treatment for all cancer patients
14 Feb 2019

Melanoma breakthrough paves way for personalised treatment for all cancer patients

Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.

Melanoma March announces 2019 Principal Partner
07 Feb 2019

Melanoma March announces 2019 Principal Partner

Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!

Swimming champion Cate Campbell spearheads national campaign to save lives from melanoma
05 Feb 2019

Swimming champion Cate Campbell spearheads national campaign to save lives from melanoma

World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.

MIA experts collaborate on groundbreaking research
16 Jan 2019

MIA experts collaborate on groundbreaking research

MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.

World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
20 Dec 2018

World-leading pathologist Associate Professor Michael Tetzlaff visits MIA

MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.

Possible PBS listing for dabrafenib and trametinib
18 Dec 2018

Possible PBS listing for dabrafenib and trametinib

Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.

Arden Anglican School wins SunSafe Ambassador competition
13 Dec 2018

Arden Anglican School wins SunSafe Ambassador competition

Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.

DON'T CLOUD THE SUN-SAFE MESSAGE
08 Dec 2018

DON'T CLOUD THE SUN-SAFE MESSAGE

Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.

Professor Georgina Long named as one of world's most highly cited researchers
04 Dec 2018

Professor Georgina Long named as one of world's most highly cited researchers

Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.

Aussies need to protect themselves from 'everyday' sun damage
01 Dec 2018

Aussies need to protect themselves from 'everyday' sun damage

‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.

The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
29 Nov 2018

The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma

A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.

Major award for world-leaders in melanoma research
09 Nov 2018

Major award for world-leaders in melanoma research

Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.